Medtronic (NYSE:MDT) has launched its MiniMed Mio Advance infusion sets, which are designed for people managing their diabetes with insulin pump therapy.
The medtech titan touted its product, which was developed by ConvaTec, as boasting a user-friendly design that allows patients to access hard-to-reach sites, like the lower back. The infusion system has no visible needle and features a built-in insertion device, according to Medtronic.
As part of an initial product introduction period, Medtronic launched the MiniMed Mio infusion sets in select countries between November of 2017 and January of 2018. Medtronic reported that more than 85% of the 200 people who used the infusion sets during that time said that the MiniMed Mio was better than their previous infusion set.
“Early feedback on the Mio Advance infusion set has been fantastic,” Annette Brüls, president of diabetes service & solutions at Medtronic, said in prepared remarks. “Our goal is to continuously improve and innovate on core technologies to help people with diabetes continue to experience greater freedom and better health. We are excited to leverage the MiniMed Mio Advance as a platform for future infusion set innovations.”
“We are very excited to launch this innovative new product with Medtronic Diabetes,” John Lindskog, president of infusion devices at ConvaTec, added. “Ensuring patient access to the latest technology through one of the world’s largest insulin pump manufacturers is instrumental to the product’s success, and helps to further strengthen our partnership.”
Medtronic expects that the MiniMed Mio infusion sets will be commercially available in Canada, Hong Kong and certain countries in Europe between February and April of 2018. The company also plans to expand the product’s availability to other countries later this year.
